Two structural modifications give it the long plasma half-life that distinguishes it from native GLP-1: an aminoisobutyric acid (Aib) substitution at position 8 (which blocks DPP-4 enzymatic cleavage) and a fatty di-acid chain attached at lysine-26 (which drives reversible albumin binding)
This is exactly why the whole 503A business should NOT be manufacturing sterile injectables
For ideal results, speak with our medical team to find out which add-on best matches your health goals
The response of different patients to GLP-1RAs may be different, and some patients may not be able to achieve the expected hypoglycemic effect
To be honest, I was a little scared
[DOI] [PubMed] [Google Scholar] 78.Astrup A., Rssner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., Madsen J., Rasmussen M.F., Lean M.E